Copanlisib

PI3K-alpha inhibition transiently impairs endothelial nitric-oxide signaling and insulin-mediated glucose handling, producing a sharp, infusion-day spike in blood pressure and glucose. The hypertension is a hemodynamic/vascular phenomenon; the hyperglycemia is on-target insulin resistance. Both resolve as drug levels fall, so the kidney is exposed to a transient pressure and osmotic load rather than a fixed structural lesion. Severe uncontrolled hypertension or marked hyperglycemia could theoretically contribute to hemodynamic AKI.

Predictable blood-pressure rise (often peaking ~2-5 h post-infusion) and hyperglycemia on each treatment day, both typically normalizing by the following morning; symptomatic patients may report headache or flushing. Persistent renal dysfunction is unusual.

Acute and infusion-bound — within hours of each dose, resolving within ~24 h.

Intravenous pan-class-I PI3K inhibitor with predominant activity against the alpha and delta isoforms. Intermittent IV dosing blocks PI3K/AKT signaling in follicular and other indolent B-cell lymphomas.

Manage the acute hypertensive episode with antihypertensives and the hyperglycemia with short-acting agents/insulin as needed; both usually self-resolve before the next cycle. Optimize baseline BP and glucose between cycles. Dose-interrupt or reduce for recurrent grade 3+ events. Sustained AKI is rare and managed supportively.